XML 21 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
Note 4 - Stockholders' Equity
6 Months Ended
Jun. 30, 2017
Notes to Financial Statements  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
NOTE
4:–
STOCKHOLDERS’ EQUITY
 
a. On
December 
30,
2005,
the Company’s board of directors adopted the Varonis Systems, Inc.
2005
Stock Plan (the
“2005
Stock Plan”). As of
December 
31,
2013,
the Company had reserved
4,713,319
shares of common stock available for issuance to employees, directors, officers and consultants of the Company and its subsidiaries. The options generally vest over
four
years.
No
awards were granted under the
2005
Stock Plan subsequent to
December 
31,
2013,
and
no
further awards will be granted under the
2005
Stock Plan.
 
On
November 
14,
2013,
the Company’s board of directors adopted the Varonis Systems, Inc.
2013
Omnibus Equity Incentive Plan (the
“2013
Plan”) which was subsequently approved by the Company’s stockholders. The Company initially reserved
1,904,633
shares of common stock available for issuance under the
2013
Plan to employees, directors, officers and consultants of the Company and its subsidiaries. The number of shares of common stock available for issuance under the
2013
Plan was increased on
January 
1,
2016
and will be increased on each
January 
1
thereafter by
four
percent (
4%
) of the number of shares of common stock issued and outstanding on each
December 
31
immediately prior to the date of increase (rounded down to the nearest whole share), but the amount of each increase will be limited to the number of shares of common stock necessary to bring the total number of shares of Common Stock available for grant and issuance under the
2013
Plan to
five
percent (
5%
) of the number of shares of common stock issued and outstanding on each
December 
31.
On
January 1, 2016
and
2017,
the share reserve under the
2013
Plan was automatically increased by
1,042,766
and
1,072,870
shares, respectively. Awards granted under the
2013
Plan generally vest over
four
years. Any award that is forfeited or canceled before expiration becomes available for future grants under the
2013
Plan.
 
A summary of employees’ stock options activities during the
six
months ended
June 30, 2017
is as follows:
 
    Six Months Ended
June 30, 2017 (unaudited)
    Number   Weighted
average
exercise price
  Aggregate
intrinsic value
(in thousands)
  Weighted
average
remaining
contractual life
(years)
                 
Options outstanding as of January 1, 2017    
2,388,348
    $
15.243
    $
30,025
     
5.861
 
Granted    
-
    $
-
     
 
     
 
 
Exercised    
(330,351
)   $
10.324
     
 
     
 
 
Forfeited    
(72,893
)   $
18.148
     
 
     
 
 
                                 
Options outstanding as of June 30, 2017    
1,985,104
    $
15.941
    $
42,589
     
5.035
 
                                 
Options exercisable at the end of the period    
1,633,271
    $
14.216
    $
37,856
     
4.624
 
 
The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders exercised their options on the last date of the exercise period. Total intrinsic value of options exercised for the
six
months ended
June 30, 2017
was
$7,500.
 
b. The options outstanding as of
June 30, 2017 (
unaudited) have been separated into ranges of exercise price as follows:
 
Range of exercise price
 
 
Options

outstanding

as of

June 30,

2017
 
 
 
Weighted

average

remaining

contractual

life (years)
 
 
 
Weighted

average

exercise price
 
 
 
Options

exercisable

as of

June 30,

2017
 
 
 
Weighted

average

remaining

contractual

life (years)
 
 
 
Weighted

average

exercise price

of options

exercisable
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$1.039
-
$1.576
 
 
575,859
 
 
 
1.855
 
 
$
1.329
 
 
 
575,859
 
 
 
1.855
 
 
$
1.329
 
$6.230
-
8.800
 
 
70,930
 
 
 
4.266
 
 
$
7.032
 
 
 
70,930
 
 
 
4.266
 
 
$
7.032
 
$12.470
-
16.870
 
 
297,114
 
 
 
6.172
 
 
$
13.429
 
 
 
263,780
 
 
 
5.859
 
 
$
12.995
 
$19.510
-
21.660
 
 
475,348
 
 
 
6.602
 
 
$
21.202
 
 
 
311,878
 
 
 
6.512
 
 
$
21.200
 
$22.010
-
24.230
 
 
269,316
 
 
 
6.335
 
 
$
22.270
 
 
 
204,808
 
 
 
6.316
 
 
$
22.305
 
 
$29.880
 
 
 
150,887
 
 
 
7.649
 
 
$
29.880
 
 
 
86,643
 
 
 
7.649
 
 
$
29.880
 
 
$39.860
 
 
 
145,650
 
 
 
5.435
 
 
$
39.860
 
 
 
119,373
 
 
 
5.435
 
 
$
39.860
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1,985,104
 
 
 
5.035
 
 
$
15.941
 
 
 
1,633,271
 
 
 
4.624
 
 
$
14.216
 
 
c. Options issued to consultants:
 
The Company’s outstanding options granted to consultants for services as of
June 30, 2017 (
unaudited) were as follows:
 
    Options for
shares of
common stock
  Exercise price
per share
  Options
exercisable
  Exercisable
through
    (number)       (number)    
                 
February 2013    
1,500
    $
12.470
     
1,500
     
February 2023
 
August 2013    
4,188
    $
21.140
     
3,559
     
August 2023
 
March 2014    
13,100
    $
39.860
     
10,546
     
March 2024
 
May 2014    
6,250
    $
22.010
     
4,580
     
May 2024
 
November 2014    
8,431
    $
21.660
     
4,663
     
November 2024
 
May 2015    
3,500
    $
19.510
     
1,105
     
May 2025
 
February 2016    
2,500
    $
16.870
     
832
     
February 2026
 
                                 
     
39,469
     
 
     
26,785
     
 
 
 
d.       Restricted stock units:
 
A summary of restricted stock units for employees, consultants and non-employee directors of the Company for the
six
months ended
June 30, 2017 (
unaudited) is as follows:
 
    Number of
shares
underlying
outstanding
restricted stock
units
  Weighted-
average
grant date
fair value
Unvested balance - January 1, 2017    
1,399,127
    $
19.96
 
Granted    
1,011,903
    $
28.93
 
Vested    
(309,675
)   $
20.46
 
Forfeited    
(153,200
)   $
21.40
 
Unvested balance – June 30, 2017    
1,948,155
    $
25.11
 
 
e. As of
June 30, 2017,
there was
$4,378
and
$43,752
of total unrecognized compensation cost related to unvested employee stock options and unvested restricted stock units, respectively. This cost is expected to be recognized over a period of approximately
1.242
years and
3.083
years for stock options and restricted stock units, respectively.
 
f.
 
2015
Employee Stock Purchase Plan
 
On
May 5, 2015,
the Company’s stockholders approved the Varonis Systems, Inc.
2015
Employee Stock Purchase Plan (the “ESPP”), which the Company’s board of directors had adopted on
March 19, 2015.
The ESPP became effective as of
June 30, 2015.
The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to
15%
of their eligible compensation, at
not
less than
85%
of the fair market value of the Company’s common stock on the
first
day or last trading day in the offering period, subject to any plan limitations. The Company initially reserved
500,000
shares of common stock for issuance under the ESPP. The number of shares available for issuance under the ESPP was increased on
January 1, 2016,
and will increase each
January 1
thereafter, by an amount equal to the lesser of (i)
one
percent (
1%
) of the number of shares of common stock issued and outstanding on each
December 31
immediately prior to the date of increase, except that the amount of each such increase will be limited to the number of shares of common stock necessary to bring the total number of shares of common stock available for issuance under the ESPP to
two
percent (
2%
) of the number of shares of common stock issued and outstanding on each such
December 31,
or (ii)
400,000
shares of common stock. On
January 1, 2016
and
2017,
the share reserve under the ESPP was automatically increased by
21,383
and
158,695
shares, respectively. The ESPP will continue in effect until the earlier of (i) the date when
no
shares of common stock are available for issuance thereunder or (ii)
June 30, 2025;
unless terminated prior thereto by the Company’s board of directors or compensation committee, each of which has the right to terminate the ESPP at any time.
 
g.
 
Stock-based compensation expense for employees and consultants:
 
The Company recognized non-cash stock-based compensation expense in the consolidated statements of operations as follows:
 
    Three Months Ended
June 30,
  Six Months Ended
June 30,
    2017   2016   2017   2016
    (unaudited)   (unaudited)
    (in thousands)   (in thousands)
                 
Cost of revenues   $
273
    $
172
    $
500
    $
318
 
Research and development    
1,301
     
793
     
2,431
     
1,458
 
Sales and marketing    
2,362
     
1,628
     
4,421
     
2,803
 
General and administrative    
1,323
     
780
     
2,311
     
1,418
 
                                 
Total   $
5,259
    $
3,373
    $
9,663
    $
5,997
 
 
Since the Company is in a net loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all the periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. There are
3,972,728
and
4,091,928
potentially dilutive shares from the conversion of outstanding RSUs and stock options that were
not
included in the calculation of diluted net loss per share as of
June 30, 2017
and
2016,
respectively.